Which has better valuation & earnings, TLX or TBPH?

Theravance Biopharma has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.70 -$7.12M N/A N/A Theravance Biopharma $107.46M 7.64 $105.89M $2.20 7.24

Does the media refer more to TLX or TBPH?

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.31 beat Telix Pharmaceuticals' score of 0.38 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TBPH or DYN?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 6 mentions for Dyne Therapeutics and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.31 beat Dyne Therapeutics' score of 1.20 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TBPH or RCUS?

In the previous week, Arcus Biosciences had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Arcus Biosciences and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.31 beat Arcus Biosciences' score of 0.09 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to TNGX or TBPH?

In the previous week, Tango Therapeutics had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Tango Therapeutics and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.31 beat Tango Therapeutics' score of 0.93 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TBPH or GMTX?

Theravance Biopharma currently has a consensus target price of $21.83, indicating a potential upside of 37.14%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.75 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Theravance Biopharma (TBPH) Competitors

$15.92 +0.34 (+2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$15.89 -0.03 (-0.19%)

As of 04:10 PM Eastern

Compare

TBPH vs. TLX, DYN, RCUS, TNGX, and GMTX

Should you buy Theravance Biopharma stock or one of its competitors? MarketBeat compares Theravance Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Theravance Biopharma include Telix Pharmaceuticals (TLX), Dyne Therapeutics (DYN), Arcus Biosciences (RCUS), Tango Therapeutics (TNGX), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Telix Pharmaceuticals presently has a consensus target price of $21.13, suggesting a potential upside of 140.88%. Theravance Biopharma has a consensus target price of $21.83, suggesting a potential upside of 37.14%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75

Theravance Biopharma has a net margin of 104.34% compared to Telix Pharmaceuticals' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Theravance Biopharma	104.34%	18.84%	10.94%

99.1% of Theravance Biopharma shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Theravance Biopharma has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.70	-$7.12M	N/A	N/A
Theravance Biopharma	$107.46M	7.64	$105.89M	$2.20	7.24

Telix Pharmaceuticals has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.31 beat Telix Pharmaceuticals' score of 0.38 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Theravance Biopharma beats Telix Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Theravance Biopharma compare to Dyne Therapeutics?

Theravance Biopharma (NASDAQ:TBPH) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Theravance Biopharma has a net margin of 104.34% compared to Dyne Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Theravance Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Theravance Biopharma has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	7.64	$105.89M	$2.20	7.24
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Theravance Biopharma presently has a consensus price target of $21.83, indicating a potential upside of 37.14%. Dyne Therapeutics has a consensus price target of $35.00, indicating a potential upside of 94.55%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

In the previous week, Dyne Therapeutics had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 6 mentions for Dyne Therapeutics and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.31 beat Dyne Therapeutics' score of 1.20 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Theravance Biopharma beats Dyne Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Arcus Biosciences?

Theravance Biopharma (NASDAQ:TBPH) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Arcus Biosciences had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Arcus Biosciences and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.31 beat Arcus Biosciences' score of 0.09 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Theravance Biopharma has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	7.64	$105.89M	$2.20	7.24
Arcus Biosciences	$247M	12.16	-$353M	-$3.18	N/A

Theravance Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Theravance Biopharma presently has a consensus target price of $21.83, suggesting a potential upside of 37.14%. Arcus Biosciences has a consensus target price of $33.89, suggesting a potential upside of 41.90%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Theravance Biopharma has a net margin of 104.34% compared to Arcus Biosciences' net margin of -156.36%. Theravance Biopharma's return on equity of 18.84% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Theravance Biopharma beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tango Therapeutics presently has a consensus price target of $32.27, suggesting a potential upside of 50.32%. Theravance Biopharma has a consensus price target of $21.83, suggesting a potential upside of 37.14%. Given Tango Therapeutics' higher possible upside, equities analysts plainly believe Tango Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75

Theravance Biopharma has a net margin of 104.34% compared to Tango Therapeutics' net margin of -151.15%. Theravance Biopharma's return on equity of 18.84% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Theravance Biopharma	104.34%	18.84%	10.94%

Theravance Biopharma has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	49.79	-$101.59M	-$0.83	N/A
Theravance Biopharma	$107.46M	7.64	$105.89M	$2.20	7.24

Tango Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

In the previous week, Tango Therapeutics had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Tango Therapeutics and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.31 beat Tango Therapeutics' score of 0.93 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Theravance Biopharma beats Tango Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Gemini Therapeutics?

Theravance Biopharma (NASDAQ:TBPH) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Theravance Biopharma had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Theravance Biopharma and 0 mentions for Gemini Therapeutics. Theravance Biopharma's average media sentiment score of 1.31 beat Gemini Therapeutics' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Theravance Biopharma	Positive
Gemini Therapeutics	Neutral

Theravance Biopharma currently has a consensus target price of $21.83, indicating a potential upside of 37.14%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Theravance Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	7.64	$105.89M	$2.20	7.24
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Theravance Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Gemini Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

Theravance Biopharma beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBPH vs. The Competition

Export

Metric	Theravance Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$803.20M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	7.24	17.69	22.39	24.18
Price / Sales	7.64	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	2.72	3.85	9.84	6.72
Net Income	$105.89M	$75.85M	$3.57B	$337.19M
7 Day Performance	-2.09%	-1.67%	-1.16%	0.48%
1 Month Performance	-5.18%	22.18%	3.85%	5.07%
1 Year Performance	43.17%	21.83%	27.40%	34.25%

Theravance Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBPH Theravance Biopharma	3.4782 of 5 stars	$15.92 +2.2%	$21.83 +37.1%	+39.7%	$803.20M	$107.46M	7.24	110	Positive News
TLX Telix Pharmaceuticals	4.4826 of 5 stars	$9.12 -3.3%	$21.13 +131.7%	-45.5%	$3.20B	$803.79M	N/A	1,184	Gap Up
DYN Dyne Therapeutics	3.099 of 5 stars	$17.56 -9.2%	$35.00 +99.3%	+35.7%	$3.20B	N/A	N/A	100	Positive News
RCUS Arcus Biosciences	2.4512 of 5 stars	$24.55 -3.1%	$33.89 +38.0%	+165.3%	$3.19B	$236M	N/A	500
TNGX Tango Therapeutics	2.889 of 5 stars	$21.89 -0.4%	$32.27 +47.4%	+746.5%	$3.18B	$62.38M	N/A	90	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBPH) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Competitors

TBPH vs. TLX, DYN, RCUS, TNGX, and GMTX

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Summary

How does Theravance Biopharma compare to Dyne Therapeutics?

Summary

How does Theravance Biopharma compare to Arcus Biosciences?

Summary

How does Theravance Biopharma compare to Tango Therapeutics?

Summary

How does Theravance Biopharma compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Competitors

TBPH vs. TLX, DYN, RCUS, TNGX, and GMTX

How does Theravance Biopharma compare to Telix Pharmaceuticals?

Do analysts recommend TLX or TBPH?

Is TLX or TBPH more profitable?

Do insiders & institutionals believe in TLX or TBPH?

Which has better valuation & earnings, TLX or TBPH?

Which has more volatility & risk, TLX or TBPH?

Does the media refer more to TLX or TBPH?

Summary

How does Theravance Biopharma compare to Dyne Therapeutics?

Is TBPH or DYN more profitable?

Which has more risk and volatility, TBPH or DYN?

Do institutionals and insiders have more ownership in TBPH or DYN?

Which has stronger valuation and earnings, TBPH or DYN?

Do analysts recommend TBPH or DYN?

Does the media favor TBPH or DYN?

Summary

How does Theravance Biopharma compare to Arcus Biosciences?

Does the media prefer TBPH or RCUS?

Which has better earnings & valuation, TBPH or RCUS?

Which has more risk and volatility, TBPH or RCUS?

Do analysts rate TBPH or RCUS?

Is TBPH or RCUS more profitable?

Do institutionals & insiders hold more shares of TBPH or RCUS?

Summary

How does Theravance Biopharma compare to Tango Therapeutics?

Do insiders & institutionals hold more shares of TNGX or TBPH?

Do analysts prefer TNGX or TBPH?

Is TNGX or TBPH more profitable?

Which has better earnings and valuation, TNGX or TBPH?

Which has more risk & volatility, TNGX or TBPH?

Does the media refer more to TNGX or TBPH?

Summary

How does Theravance Biopharma compare to Gemini Therapeutics?

Do institutionals & insiders have more ownership in TBPH or GMTX?

Does the media prefer TBPH or GMTX?

Do analysts recommend TBPH or GMTX?

Which has better valuation & earnings, TBPH or GMTX?

Which has more volatility & risk, TBPH or GMTX?

Is TBPH or GMTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools